查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1748677

結締組織疾病治療市場（按疾病、藥物、配銷通路、國家和地區）—2024 年至 2032 年的行業分析、市場規模、市場佔有率和預測

Connective Tissue Disease Treatment Market, By Disease, By Drug, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年結締組織疾病治療市場規模價值為 241.691 億美元，2024 年至 2032 年的複合年成長率為 5.89%。

結締組織疾病治療市場-市場動態

自體免疫疾病盛行率上升

類風濕性關節炎、紅斑性狼瘡和硬皮症等自體免疫疾病的發生率不斷上升，是結締組織疾病治療市場的主要驅動力。隨著全球範圍內越來越多的人被診斷出患有這些慢性疾病，對有效治療方案的需求也持續成長。人口老化、認知度的提高以及診斷能力的提升有助於更早發現和開始治療。患者數量的激增迫使製藥公司投資於新型療法的研發，包括生物製劑和標靶免疫抑制劑。因此，這一趨勢正在推動市場成長，並擴大先進治療方案的可用性。

結締組織疾病治療市場-關鍵見解

根據我們的研究分析師，全球結締組織疾病治療市場預計在 2024 年至 2032 年期間的複合年成長率約為 5.89%。

2023 年按疾病細分，類風濕性關節炎 (RA) 類別佔據了市場主導地位。

根據藥物，生物製藥部門在 2023 年創造了最多的收入。

按地區分類，2023年北美是收入最高的地區。

結締組織疾病治療市場-細分分析：

全球結締組織疾病治療市場分為三類：疾病、藥物、配銷通路和地區。

結締組織疾病治療市場按疾病類型分為幾個主要領域：類風濕性關節炎 (RA)、系統性紅斑狼瘡 (SLE)、硬皮症、多發性肌炎、皮肌炎、乾燥症、混合性結締組織疾病 (MCTD)、未分化結締組織疾病 (UCTD) 和其他結締組織疾病。每種疾病都需要針對性治療，通常涉及免疫抑制劑、生物製劑和症狀管理策略。其中，類風濕性關節炎 (RA) 因其高發病率及其對患者生活品質的重大影響而成為主要領域。 RA 驅動著大部分市場需求，生物療法和改善病情的抗風濕藥物 (DMARD) 的持續進步，提高了療效並改善了患者預後。 RA 發病率的上升，加上治療方案的不斷創新，鞏固了其在市場上的領先地位。

結締組織疾病治療市場按藥物類型細分為藥品和生物製藥。藥品主要包括傳統藥物，如非類固醇類抗發炎藥物 (NSAID)、皮質類固醇和免疫抑制藥物，用於控制發炎和控制症狀。生物製藥涵蓋生物製劑，如單株抗體、標靶治療和其他先進的生物療法，旨在改變疾病進展和免疫系統反應。其中，生物製藥因其在治療複雜自體免疫疾病方面的卓越功效而佔據市場主導地位。生物製劑的興起，尤其是在類風濕性關節炎和狼瘡等疾病中的興起，徹底改變了治療模式，為患者提供了更個人化和有效的治療方案。在持續的研究、新藥核准和更好的患者治療效果的支持下，生物製藥持續推動市場成長。

結締組織疾病治療市場-地理洞察

從地理分佈來看，結締組織疾病治療市場分佈於北美、亞太地區、拉丁美洲、歐洲、中東和非洲。這些區域根據業務來源國進一步分類。

北美是結締組織疾病治療市場的主導地區，這主要得益於類風濕性關節炎、紅斑性狼瘡和硬皮症等自體免疫疾病的高發性。美國憑藉其先進的醫療基礎設施、早期診斷以及人口老化（這些疾病更容易引發這些疾病）佔據了顯著的市場佔有率。該地區也受益於大型製藥和生物製藥公司的存在，這些公司在新療法的研發上投入了大量資金。此外，優惠的報銷政策和人們對自體免疫疾病認知的提高也促進了市場的成長。對創新生物製劑和免疫抑制劑的需求進一步加速了該地區的主導地位，使其在市場規模和治療進展方面都處於領先地位。

歐洲是結締組織疾病治療市場的另一個主導地區，這得益於其自體免疫疾病發病率的不斷上升、完善的醫療保健體係以及先進療法的廣泛普及。德國、法國、英國和義大利等國家是該市場的主要貢獻者，這些國家對類風濕性關節炎和狼瘡等疾病的認知日益加深。歐盟核准新藥的監管框架，加上支持性的公共醫療保健體系，促進了創新療法的可用性和可近性。此外，歐洲是醫學研究和生物製藥創新的中心，許多公司專注於開發新的生物製劑和療法。領先製藥公司的強大影響力以及對自體免疫疾病研究不斷成長的投資，進一步鞏固了歐洲作為主要市場參與者的地位。

結締組織疾病治療市場-競爭格局：

結締組織疾病治療市場的競爭態勢由老牌製藥巨頭和新興生物製藥公司共同塑造，這些公司均專注於創新並拓展產品組合。艾伯維、安進、勃林格殷格翰、百時美施貴寶和羅氏等主要公司憑藉種類繁多的生物製劑和免疫抑制劑佔據市場主導地位，並大力投資研發以提高療效和安全性。新進業者也透過標靶療法和個人化醫療方法推動市場發展。這種競爭環境促進了持續創新，推動著為結締組織疾病患者開發更有效、更方便的治療方法。

最新動態：

2025年2月，艾伯維以2.5億美元收購Celsius Therapeutics，加強了對自體免疫疾病的關注。 Celsius正在開發CEL383，這是一種針對與發炎性腸道疾病(IBD)相關的基因TREM1的口服抗體。此次收購補充了艾伯維多元化免疫學產品線的策略，尤其是在其從Humira轉向Skyrizi和Rinvoq等較新的療法之際。

2024年6月，輝瑞推出了一種旨在改善狼瘡患者預後的新型生物療法。這項進展彰顯了輝瑞致力於滿足自體免疫疾病領域未滿足需求的承諾。該療法是輝瑞增強其免疫學和自體免疫疾病治療產品組合的更廣泛策略的一部分。

目錄

第1章：結締組織疾病治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 結締組織疾病治療市場片段（依疾病）
    • 結締組織疾病治療市場（按藥物）摘要
    • 結締組織疾病治療市場（按配銷通路）
    • 結締組織疾病治療市場（按國家/地區）
    • 結締組織疾病治療市場（按地區）
  • 競爭洞察

第3章：結締組織疾病治療主要市場趨勢

  • 結締組織疾病治療市場促進因素
    • 市場促進因素的影響分析
  • 結締組織疾病治療市場限制
    • 市場限制的影響分析
  • 結締組織疾病治療市場機會
  • 結締組織疾病治療市場未來趨勢

第4章：結締組織疾病治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：結締組織疾病治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • 新冠疫情後影響分析
    • 表現最佳的市場區隔
    • 邊際成長細分市場
    • 最鬆散的細分市場
    • 邊際損失市場區隔

第6章：結締組織疾病治療市場格局

  • 2023年結締組織疾病治療市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：結締組織疾病治療市場 - 按疾病

  • 概述
    • 按疾病細分的佔有率分析
    • 類風濕性關節炎（RA）
    • 系統性紅斑狼瘡（SLE）
    • 硬皮症
    • 多發性肌炎
    • 皮肌炎
    • 乾燥症
    • 混合結締組織疾病（MCTD）
    • 未分化結締組織疾病（UCTD）
    • 其他結締組織疾病

第 8 章：結締組織疾病治療市場 - 按藥物

  • 概述
    • 按藥物細分的市佔率分析
    • 製藥
      • 非類固醇抗發炎藥（NSAID）
      • 改善病情的抗風濕藥物（DMARDs）
      • 皮質類固醇
      • 其他藥品
    • 生物製藥
      • 生物製劑
      • TNF抑制劑
      • IL-6抑制劑
      • B細胞抑制劑
      • T細胞抑制劑
      • 其他生物製劑
      • 生物相似藥

第9章：結締組織疾病治療市場－按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 10 章：結締組織疾病治療市場-按地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美結締組織疾病治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按疾病）
    • 北美市場規模及預測（按藥品）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲結締組織疾病治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按疾病）
    • 歐洲市場規模及預測（按藥品）
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區結締組織疾病治療主要製造商
    • 亞太市場規模及預測（按國家/地區）
    • 亞太市場規模及預測（按疾病）
    • 亞太市場規模及預測（按藥品）
    • 亞太市場規模及預測（按配銷通路）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲結締組織疾病治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按疾病）
    • 拉丁美洲市場規模及預測（按藥品）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲結締組織疾病治療主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按疾病）
    • 中東和非洲市場規模及預測（按藥品）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：關鍵供應商分析-結締組織疾病治療產業

  • 競爭儀錶板
  • 公司簡介
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5227

REPORT HIGHLIGHT

Connective Tissue Disease Treatment Market size was valued at USD 24,169.10 Million in 2024, expanding at a CAGR of 5.89% from 2024 to 2032.

Connective tissue disease treatment involves managing autoimmune conditions that affect tissues like skin, joints, muscles, and organs. Treatment typically focuses on reducing inflammation, controlling immune system activity, and relieving symptoms. Common approaches include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants, and disease-modifying antirheumatic drugs (DMARDs). Biologic therapies may be used in severe cases. Physical therapy and lifestyle modifications support mobility and overall health. Treatment is tailored to the specific disease, such as lupus, scleroderma, or rheumatoid arthritis, and varies based on severity and organ involvement. Regular monitoring and multidisciplinary care are essential to prevent complications and improve long-term outcomes.

Connective Tissue Disease Treatment Market- Market Dynamics

Rising Prevalence of Autoimmune Disorders

The growing incidence of autoimmune diseases such as rheumatoid arthritis, lupus, and scleroderma is a major driver for the connective tissue disease treatment market. As more individuals are diagnosed with these chronic conditions globally, the demand for effective treatment options continues to rise. Aging populations, increased awareness, and improved diagnostic capabilities contribute to earlier detection and treatment initiation. This surge in patient populations compels pharmaceutical companies to invest in research and development of novel therapies, including biologics and targeted immunosuppressants. Consequently, this trend is fueling market growth and expanding the availability of advanced therapeutic solutions.

Connective Tissue Disease Treatment Market- Key Insights

According to our research analyst, the global Connective Tissue Disease Treatment Market is expected to develop at a CAGR of approximately 5.89% between 2024-2032.

Segmented by Disease in 2023, the Rheumatoid Arthritis (RA) category dominated the market.

Based on Drug, the Biopharmaceuticals segment generated the most income in 2023.

On the basis of region, in 2023, North America was the region with the highest revenue.

Connective Tissue Disease Treatment Market- Segmentation Analysis:

The global Connective Tissue Disease Treatment Market is divided into three categories: Disease, Drug, Distribution Channel and Region.

The connective tissue disease treatment market is categorized by disease type into several key segments: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Scleroderma, Polymyositis, Dermatomyositis, Sjogren's Syndrome, Mixed Connective Tissue Disease (MCTD), Undifferentiated Connective Tissue Disease (UCTD), and other connective tissue diseases. Each condition requires a tailored treatment approach, often involving immunosuppressants, biologics, and symptom management strategies. Among these, Rheumatoid Arthritis (RA) is the dominant segment due to its high prevalence and the significant impact it has on patients' quality of life. RA drives the majority of market demand, with ongoing advancements in biologic therapies and disease-modifying antirheumatic drugs (DMARDs) that offer improved efficacy and patient outcomes. The rising incidence of RA, combined with continuous innovation in treatment options, solidifies its leading position in the market.

The connective tissue disease treatment market is segmented by drug type into Pharmaceuticals and Biopharmaceuticals. Pharmaceuticals primarily include traditional drugs like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive medications that help control inflammation and manage symptoms. Biopharmaceuticals encompass biologic agents such as monoclonal antibodies, targeted therapies, and other advanced biologic treatments that aim to modify the disease's progression and immune system response. Among these, Biopharmaceuticals dominate the market due to their superior efficacy in treating complex autoimmune conditions. The rise of biologics, particularly in diseases like rheumatoid arthritis and lupus, has revolutionized treatment paradigms, offering patients more personalized and effective therapies. Biopharmaceuticals continue to drive market growth, supported by ongoing research, new drug approvals, and better patient outcomes.

Connective Tissue Disease Treatment Market- Geographical Insights

Geographically, the Connective Tissue Disease Treatment Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is the dominant region in the connective tissue disease treatment market, driven by the high prevalence of autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The United States, in particular, holds a significant market share due to advanced healthcare infrastructure, early diagnosis, and an aging population, which is more susceptible to these diseases. The region also benefits from the presence of major pharmaceutical and biopharmaceutical companies, which invest heavily in research and development of new treatments. Additionally, favorable reimbursement policies and improved awareness around autoimmune disorders contribute to the market's growth. The demand for innovative biologics and immunosuppressants further accelerates the region's dominance, making it a leader in both market size and therapeutic advancements.

Europe is another dominant region in the connective tissue disease treatment market, owing to the increasing incidence of autoimmune diseases, robust healthcare systems, and widespread availability of advanced treatments. Countries like Germany, France, the United Kingdom, and Italy are key contributors to the market, with growing awareness about diseases such as rheumatoid arthritis and lupus. The European Union's regulatory framework for approving new drugs, combined with supportive public healthcare systems, promotes the availability and accessibility of innovative treatments. Additionally, Europe is a hub for medical research and biopharmaceutical innovation, with numerous companies focused on developing new biologics and therapies. The strong presence of leading pharmaceutical companies and growing investment in autoimmune disease research further solidify Europe's position as a major market player.

Connective Tissue Disease Treatment Market- Competitive Landscape:

The competitive dynamics of the Connective Tissue Disease Treatment Market are shaped by a blend of established pharmaceutical giants and emerging biopharmaceutical companies, all focused on innovation and expanding their product portfolios. Major players such as AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, and F. Hoffmann-La Roche dominate the market with a wide range of biologics and immunosuppressants, heavily investing in research and development to improve treatment efficacy and safety. New entrants are also advancing the market with targeted therapies and personalized medicine approaches. This competitive environment fosters continuous innovation, driving the development of more effective and accessible treatments for patients with connective tissue diseases.

Recent Developments:

In February 2025, AbbVie intensified its focus on autoimmune diseases by acquiring Celsius Therapeutics for $250 million. Celsius is developing CEL383, an oral antibody targeting TREM1, a gene associated with inflammatory bowel disease (IBD). This acquisition complements AbbVie's strategy to diversify its immunology pipeline, particularly as it shifts from Humira to newer therapies like Skyrizi and Rinvoq.

In June 2024, Pfizer launched a new biologic therapy aimed at improving outcomes for patients with lupus. This development underscores Pfizer's commitment to addressing unmet needs in autoimmune diseases. The therapy is part of Pfizer's broader strategy to enhance its portfolio in immunology and autoimmune disease treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Lily
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • UCB S.A.
  • Others

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISEASE - MARKET ANALYSIS, 2019 - 2032

  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue diseases

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DRUG - MARKET ANALYSIS, 2019 - 2032

  • Pharmaceuticals
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Corticosteroids
  • Other Pharmaceuticals
  • Biopharmaceuticals
  • Biologics
  • TNF Inhibitors
  • IL-6 Inhibitors
  • B-cell Inhibitors
  • T-cell Inhibitors
  • Other Biologics
  • Biosimilars

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL INDUSTRY - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Connective Tissue Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Connective Tissue Disease Treatment Market Snippet by Disease
    • 2.1.2. Connective Tissue Disease Treatment Market Snippet by Drug
    • 2.1.3. Connective Tissue Disease Treatment Market Snippet by Distribution Channel
    • 2.1.4. Connective Tissue Disease Treatment Market Snippet by Country
    • 2.1.5. Connective Tissue Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Connective Tissue Disease Treatment Key Market Trends

  • 3.1. Connective Tissue Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Connective Tissue Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Connective Tissue Disease Treatment Market Opportunities
  • 3.4. Connective Tissue Disease Treatment Market Future Trends

4. Connective Tissue Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Connective Tissue Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Connective Tissue Disease Treatment Market Landscape

  • 6.1. Connective Tissue Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Connective Tissue Disease Treatment Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
    • 7.1.2. Rheumatoid Arthritis (RA)
    • 7.1.3. Systemic Lupus Erythematosus (SLE)
    • 7.1.4. Scleroderma
    • 7.1.5. Polymyositis
    • 7.1.6. Dermatomyositis
    • 7.1.7. Sjogren's Syndrome
    • 7.1.8. Mixed Connective Tissue Disease (MCTD)
    • 7.1.9. Undifferentiated Connective Tissue Disease (UCTD)
    • 7.1.10. Other connective tissue diseases

8. Connective Tissue Disease Treatment Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2023 & 2032 (%)
    • 8.1.2. Pharmaceuticals
      • 8.1.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 8.1.2.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 8.1.2.3. Corticosteroids
      • 8.1.2.4. Other Pharmaceuticals
    • 8.1.3. Biopharmaceuticals
      • 8.1.3.1. Biologics
      • 8.1.3.1.1. TNF Inhibitors
      • 8.1.3.1.2. IL-6 Inhibitors
      • 8.1.3.1.3. B-cell Inhibitors
      • 8.1.3.1.4. T-cell Inhibitors
      • 8.1.3.1.5. Other Biologics
      • 8.1.3.2. Biosimilars

9. Connective Tissue Disease Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Connective Tissue Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Connective Tissue Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Connective Tissue Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Connective Tissue Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Connective Tissue Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Connective Tissue Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Connective Tissue Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. AbbVie, Inc.
    • 11.2.2. Amgen, Inc.
    • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. F. Hoffmann-La Roche Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Lily
    • 11.2.8. Novartis AG
    • 11.2.9. Pfizer Inc.
    • 11.2.10. Regeneron Pharmaceuticals Inc.
    • 11.2.11. UCB S.A.
    • 11.2.12. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us